Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 30, Issue 24, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2020.127614
Keywords
Congenital disorders of glycosylation; N-glycan; Biomarker; ALG1-CDG; Liposome; Immune response
Categories
Funding
- National Natural Science Foundation of China [21778023, 21807048, 31971216]
- Natural Science Foundation of Jiangsu Province [BK20170174]
- Shandong Provincial Major Scientific and Technological Innovation Project [2019JZZY011006]
- Open Project Program of Key Laboratory of Carbohydrate Chemistry and Biotechnology [KLCCB-KF201604]
- Top-notch Academic Programs Project of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Congenital disorders of glycosylation (CDG) are a growing group diseases that result from defects in genes involved in glycan biosynthesis pathways. One tetrasaccharide, i.e., Neu5Ac-alpha 2, 6-Gal-beta 1, 4-GlcNAc-beta 1, 4-GlcNAc, was recently reported as the biomarker of ALG1-CDG, the disease caused by ALG1 deficiency. To develop a novel diagnostic method for ALG1-CDG, chemo-enzymatic synthesis of the tetrasaccharide biomarker linked to phytanyl phosphate and the biomarker's immune stimulation were investigated in this study. The immunization study using liposomes bearing phytanyl-linked tetrasaccharide revealed that they stimulated a moderate immune response. The induced antibody showed strong binding specificity for the ALG1-CDG biomarker, indicating its potential in medical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
